Immune cell therapy for HPV-16 advanced cancers
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack HPV-16 related cancers. It is for people with advanced solid tumors that have not responded to other treatments, and it aims to help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have an advanced solid tumor (like cervical, head and neck, or anal cancer) that has not responded to standard treatments or you cannot tolerate them.
- Your tumor is HPV type 16 positive, and you have the HLA-A*02:01 marker in your blood.
- You are able to care for yourself and are up and about more than half the day (ECOG 0-1).
- You have at least one measurable tumor that can be seen on scans.
- You have not had certain other treatments recently (chemotherapy, targeted therapy, or immunotherapy within 2 weeks; radiation within 4 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
This trial tests a new cell therapy called TRTs for people with advanced cancers like stomach, esophagus, cervical, breast, or lung cancer that no longer respond to standard treatments. The therapy uses your own tumor tissue or fluid to create a personalized treatment.
This study tests a new treatment using your own immune cells (called SCG142) that are specially trained to attack cancer cells linked to HPV 16 or 52. It may help people with advanced squamous cell cancers who have not gotten better with standard treatments.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.